Groupe Francais De Pneumo-Cancerologie   Report issue

Academic/Hospital Phase 3
Founded: Clermont-Ferrand France (1980)

Organization Overview

First Clinical Trial
1998
NCT00037713
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Groupe Francais De Pneumo-Cancerologie

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Small Cell (Phase 3)

Lung Neoplasms (Phase 3)

Mesothelioma (Phase 3)

Neoplasm Metastasis (Phase 3)

Small Cell Lung Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 10